Dec 22, 2025 07:06AM
Oct 24, 2025 08:29AM
Aug 26, 2025 05:26AM
Aug 25, 2025 04:30PM
Aug 25, 2025 02:15AM
Jul 6, 2025 10:00AM
Jun 30, 2025 04:13PM Citi on argenx SE (ARGX): 'We remain Buyers on today’s weakness'
Jun 30, 2025 11:40AM
Apr 11, 2025 09:44AM
Apr 11, 2025 07:08AM
Apr 11, 2025 06:36AM
Apr 11, 2025 06:29AM
Apr 10, 2025 06:02PM
Apr 10, 2025 05:47PM argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy
Jan 4, 2025 04:00PM
Jan 2, 2025 12:51PM
Nov 22, 2024 11:07AM
Oct 15, 2024 01:00AM
Sep 19, 2024 01:00AM
Jul 29, 2024 06:55AM
Jul 26, 2024 06:47AM argenx SE (ARGX) PT Raised to $533 at H.C. Wainwright
Jul 16, 2024 12:15AM
Jun 24, 2024 06:58AM
Jun 24, 2024 06:35AM
Jun 21, 2024 04:52PM
Jun 21, 2024 04:50PM
Apr 16, 2024 01:00AM
Mar 27, 2024 02:00AM argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease
Feb 20, 2024 03:10AM
Feb 20, 2024 01:00AM
Jan 8, 2024 05:32AM
Jan 8, 2024 01:00AM
Jun 30, 2023 09:39AM
Jun 20, 2023 06:13PM
Jun 20, 2023 06:12PM argenx Announces U.S. Food and Drug Administration Approval of VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Generalized Myasthenia Gravis
Apr 18, 2023 01:00AM
Mar 2, 2023 01:00AM
Jan 27, 2023 01:00AM
Dec 10, 2022 11:30AM
Nov 30, 2022 06:20AM
Nov 30, 2022 01:00AM
Nov 22, 2022 01:00AM argenx Announces U.S. FDA Acceptance of Biologics License Application for Subcutaneous Efgartigimod in Generalized Myasthenia Gravis with Priority Review
Oct 27, 2022 01:00AM
Sep 21, 2022 01:00AM
Sep 21, 2022 01:00AM
Jul 28, 2022 01:00AM
May 5, 2022 05:45AM
May 5, 2022 01:00AM
May 5, 2022 01:00AM argenx Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART® (efgartigimod alfa-fcab) in Adults with Primary Immune Thrombocytopenia
Apr 5, 2022 05:58AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All